Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts' consensus: Nineteen brokerages give Structure Therapeutics a consensus rating of "Moderate Buy" with an average 12‑month price target of $109.25, while individual firms have issued targets and ratings as high as $145 (BMO) and a "strong‑buy" from Goldman Sachs.
• Recent performance and fundamentals: The stock opened at $43.56 (down ~3.9%), has a market cap of $3.09B, a 52‑week range of $15.80–$94.90, a negative PE, and it missed last quarter's EPS (reported -$0.49 vs. -$0.35 consensus) with analysts forecasting -1.36 EPS for the year.
• Institutional backing: About 91.78% of shares are institutionally owned, with large stake increases from Wellington, Avoro, Janus Henderson and a 261.4% rise by Morgan Stanley, signaling significant institutional interest.

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nineteen research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $109.25.

A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Wolfe Research assumed coverage on Structure Therapeutics in a report on Thursday, March 26th. They issued a "peer perform" rating for the company. BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, March 17th. Guggenheim increased their price objective on Structure Therapeutics from $90.00 to $140.00 and gave the stock a "buy" rating in a report on Tuesday, January 20th. Finally, The Goldman Sachs Group raised Structure Therapeutics to a "strong-buy" rating in a report on Tuesday, January 20th.

Structure Therapeutics Trading Down 3.9%

NASDAQ:GPCR opened at $43.56 on Wednesday. The firm has a market capitalization of $3.09 billion, a PE ratio of -55.14 and a beta of -1.17. The stock has a 50 day moving average of $54.56 and a 200-day moving average of $55.70. Structure Therapeutics has a 52 week low of $15.80 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, analysts predict that Structure Therapeutics will post -1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP increased its stake in shares of Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company's stock valued at $495,334,000 after acquiring an additional 1,432,797 shares during the period. Avoro Capital Advisors LLC lifted its position in Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company's stock worth $455,939,000 after purchasing an additional 1,150,000 shares during the period. Janus Henderson Group PLC lifted its position in Structure Therapeutics by 14.4% in the fourth quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company's stock worth $354,006,000 after purchasing an additional 641,322 shares during the period. BVF Inc. IL lifted its position in Structure Therapeutics by 8.6% in the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company's stock worth $241,966,000 after purchasing an additional 275,105 shares during the period. Finally, Morgan Stanley lifted its position in Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company's stock worth $145,209,000 after purchasing an additional 1,510,093 shares during the period. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.